Proof of Concept Study to Investigate ANB020 Activity in Adult Patients With Severe Eosinophilic Asthma

This is a multi-center, randomized, double-blind, placebo-controlled, proof of concept study
to assess the safety and tolerability of ANB20 in adult patients with severe eosinophilic
asthma.

Inclusion Criteria:

- Male and female patients aged ≥18 to ≤65 years and able to give informed consent.

- Patients with a confirmed clinical diagnosis of eosinophilic asthma

- History of diagnosis of eosinophilic asthma

- Severe asthma diagnosed according to the Global Initiative for Asthma (GINA) 2016

- Body mass index (BMI) of 18 to 38 kg/m2 (inclusive) and total body weight >50 kg (110
lb.).

- Women of childbearing potential must have a negative serum pregnancy test at screening
and be willing to use effective methods of contraception throughout the study.

- Male patients must be willing to use effective methods of contraception during the
entire study period.

- Patient must be on high dose ICS plus LABA.

- Willing and able to comply with the study protocol requirements.

- Have the ability to read and understand the study procedures and can communicate
meaningfully with the Investigator and staff.

Exclusion Criteria:

- Have concomitant medical condition(s) which may interfere with the Investigator's
ability to evaluate the patient's response to the IP.

- Have experienced severe life threatening anaphylactic reactions.

- Have received any IP within a period of 3 months or 5 half lives of an IP

- Have received high dose systemic corticosteroids

- Have received treatment with biologics within 3 months or 5 half lives (whichever is
longer) before screening.

- Abnormal ECG assessment at screening

- Uncontrolled hypertension, or acute ischemic cardiovascular diseases.

- If female, is pregnant or lactating, or intend to become pregnant during the study
period.

- History (or suspected history) of alcohol or substance abuse within 2 years before
screening.

- Any comorbidity that the Investigator believes is a contraindication to study
participation.

- Have any other physical, mental, or medical conditions which, in the opinion of the
Investigator, make study participation inadvisable or could confound study
assessments.

- Planned surgery during the study or 30 days before screening.

- History of malignancy within 5 years, except non melanoma skin cancer which has been
fully treated with no current active disease.